As the race to find the cure to the Chinese coronavirus intensifies, at least seven Indian pharma companies have reached the advanced level in developing a vaccine for the deadly Chinese Wuhan virus.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax, and Biological E are the Indian pharma companies that are working day and night to stop the spread of COVID19 that has already infected more than 14 million people globally.
Out of these companies, Bharat Biotech, which is developing Covaxin, has already received approval from the government to conduct the phase I and II clinical trials. It has started human clinical trials.
On the other hand, the Serum Institute, one of the leading vaccine developers in India, is expecting to develop the cure for the Chinese virus by the end of the year 2020.
Another pharma giant from India, Zydus Cadila has said that it is looking to complete clinical trials of its COVID-19 vaccine ZyCoV-D in the next 7-8 months. This means the company will be able to produce the vaccine latest by February or March 2021.
Globally, there are over 140 companies that are working on the development of the vaccine for the Chinese virus. The World Health Organisation (WHO) is closely tracking these companies. Out of them, around 12 companies are at various stages of human clinical trials of their vaccine candidates.